TrialJournal of translational medicine2023

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.

Reinhard Dummer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.